VNIM
AMRI

Vaughan Nelson Investment Management’s Albany Molecular Research Inc AMRI Stock Holding History

Vaughan Nelson Investment Management’s Portfolio AMRI Stock Details AMRI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-2,082,900
Closed -$39.1M – 193
2016
Q4 		$39.1M Buy
2,082,900
+142,525
+7% +$2.42M 0.46% 106
2016
Q3 		$32M Buy
1,940,375
+160,450
+9% +$2.38M 0.38% 115
2016
Q2 		$23.9M Buy
1,779,925
+51,175
+3% +$747K 0.3% 125
2016
Q1 		$26.4M Buy
1,728,750
+88,025
+5% +$1.38M 0.33% 120
2015
Q4 		$32.6M Buy
1,640,725
+86,925
+6% +$1.65M 0.42% 110
2015
Q3 		$27.1M Buy
1,553,800
+57,725
+4% +$1.18M 0.39% 116
2015
Q2 		$30.3M Buy
1,496,075
+26,575
+2% +$513K 0.43% 104
2015
Q1 		$25.9M Buy
1,469,500
+131,900
+10% +$2.25M 0.39% 111
2014
Q4 		$21.8M Buy
+1,337,600
New +$24.5M 0.32% 119

Other funds holding AMRI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PIP
Permian Investment Partners Dallas, Texas $911M AUM 0.66% 1-Year Est. Return
ACM
American Capital Management New York $2.23B AUM 28.03% 1-Year Est. Return
OWP
Obermeyer Wealth Partners Aspen, Colorado $2.44B AUM 24.34% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
EWM
Evercore Wealth Management New York $7.07B AUM 24.72% 1-Year Est. Return
WC
Walthausen & Co Malta, New York $120M AUM 2.66% 1-Year Est. Return

Vaughan Nelson Investment Management's AMRI Position: Q1 2017 in Review

Vaughan Nelson Investment Management sold out of Albany Molecular Research Inc (AMRI) in Q1 2017, closing a stake of 2,082,900 shares — an estimated $39.1M sold.

Vaughan Nelson Investment Management first reported a position in AMRI in Q4 2014 and held it in 9 quarters. The position peaked at $39.1M in Q4 2016. 139 funds tracked by Wall St. Rank hold AMRI as of Q1 2017.

  • Vaughan Nelson Investment Management reported no remaining Albany Molecular Research Inc position as of Q1 2017 after selling out during the quarter.
  • Vaughan Nelson Investment Management sold 2,082,900 Albany Molecular Research Inc shares in Q1 2017, an estimated $39.1M.
  • Vaughan Nelson Investment Management first reported a position in Albany Molecular Research Inc in Q4 2014 and held it in 9 quarters.
  • Vaughan Nelson Investment Management's Albany Molecular Research Inc position peaked at $39.1M in Q4 2016.
  • 139 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q1 2017.

Based on Vaughan Nelson Investment Management's 13F filing for Q1 2017, filed 15 May 2017.